Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy

Inclusion Criteria: * Histologic proof of breast cancer (invasive ductal or lobular carcinoma). Breast sarcoma and lymphoma are not eligible. * Clinical diagnosis of locally advanced breast cancer (Stage IIB (T3,N0,M0), Stage IIIA, IIIB, or IIIC, according to American Joint Committee on Cancer (AJCC) Tumour-Node-Metastasis (TNM) Cancer Staging), including inflammatory breast cancer. * Ability to undergo neoadjuvant chemotherapy. Exclusion Criteria: * Evidence of metastatic disease (identified on chest x-ray, liver ultrasound, bone scan or other imaging tests); * Previous chemotherapy or hormonal therapy for breast cancer; * Significant concurrent medical problems that result in the patient being unfit for surgery (e.g. uncontrolled diabetes, active cardiac disease, severe chronic obstructive pulmonary disease); * Known pregnancy or lactating female (e.g. positive serum beta human chorionic gonadotropin (B-hCG) pregnancy test); * Inability to lie supine for imaging with Positron Emission Tomography (PET); * Any contraindication to undergoing Magnetic Resonance Imaging (MRI) or PET; * Currently receiving Antabuse; * Inability to provide informed consent (e.g. dementia or severe cognitive impairment).